Biogen Revenue Down as Multiple Sclerosis Sales Slide

Friday, February 6, 2026 at 1:59 PM

#Alzheimer'S Drug #Biogen #Pharmaceutical Sales #Revenue

Biogen anticipates a rise in profits due to its Alzheimer's drug Leqembi and cost-cutting measures, despite a projected decline in revenue from its multiple sclerosis treatments, which have seen significant sales drops.

Markets★★Similarity: 70% · 24d ago

The Weight-Loss Price Wars Are Breaking Big Pharma’s Business Model

Prices for GLP-1s are falling fast, forcing companies to adapt.

Markets★★Similarity: 70% · 27d ago

Novartis Forecasts Profitability Hit From Generic Drug Competition in U.S.

The pharma major said it faces the largest drug-patent expiry headwind in its history this year.

Markets★★Similarity: 68% · 27d ago

Boston Scientific Profit, Sales Rise but Issues Soft Guidance

Sales rose 16%, but the medical-device maker issued a soft forecast for the year, sending shares down premarket.

Markets★★Similarity: 66% · 27d ago

AbbVie Revenue Rises on Immunology Growth

AbbVie posted higher fourth-quarter revenue on the back of growth from its immunology portfolio, led by arthritis and Crohn’s disease drugs Skyrizi and Rinvoq.

Data sourced from public RSS feeds and News APIs.

Biogen Revenue Down as Multiple Sclerosis Sales Slide

Related Articles

The Weight-Loss Price Wars Are Breaking Big Pharma’s Business Model

Novartis Forecasts Profitability Hit From Generic Drug Competition in U.S.

Boston Scientific Profit, Sales Rise but Issues Soft Guidance

AbbVie Revenue Rises on Immunology Growth

Biogen Revenue Down as Multiple Sclerosis Sales Slide

Related Articles

The Weight-Loss Price Wars Are Breaking Big Pharma’s Business Model

Novartis Forecasts Profitability Hit From Generic Drug Competition in U.S.

Boston Scientific Profit, Sales Rise but Issues Soft Guidance

AbbVie Revenue Rises on Immunology Growth